{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T17:43:24Z","timestamp":1648921404082},"reference-count":15,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.3892\/etm.2017.4077","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T13:01:41Z","timestamp":1485176501000},"page":"947-951","source":"Crossref","is-referenced-by-count":3,"title":["Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia"],"prefix":"10.3892","volume":"13","author":[{"given":"Liying","family":"Ji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyao","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,1,23]]},"reference":[{"key":"key20180108133937_b1-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","article-title":"Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"key20180108133937_b2-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ajh.24293","article-title":"Validation of the revised international prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients","volume":"91","author":"Haider","year":"2016","journal-title":"Am J Hematol"},{"key":"key20180108133937_b3-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-016-0032-7","article-title":"Identification of AIM2 as a downstream target of JAK2V617F","volume":"5","author":"Liew","year":"2016","journal-title":"Exp Hematol Oncol"},{"key":"key20180108133937_b4-etm-0-0-4077","first-page":"474","article-title":"The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis","volume":"93","author":"Mahjoub","year":"2015","journal-title":"Tunis Med"},{"key":"key20180108133937_b5-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.leukres.2015.11.002","article-title":"Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L\/K mutations","volume":"40","author":"Okabe","year":"2016","journal-title":"Leuk Res"},{"key":"key20180108133937_b6-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","article-title":"Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis","volume":"127","author":"Marty","year":"2016","journal-title":"Blood"},{"key":"key20180108133937_b7-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1002\/cncr.24440","article-title":"The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos","volume":"115","author":"Tefferi","year":"2009","journal-title":"Cancer"},{"key":"key20180108133937_b8-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"453020","DOI":"10.1155\/2015\/453020","article-title":"Proinflammatory cytokine IL-6 and JAK-STAT signaling pathway in myeloproliferative neoplasms","volume":"2015","author":"\u010coki\u0107","year":"2015","journal-title":"Mediators Inflamm"},{"key":"key20180108133937_b9-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood-2015-07-661983","article-title":"Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients","volume":"127","author":"Cabagnols","year":"2016","journal-title":"Blood"},{"key":"key20180108133937_b10-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Feenstra","year":"2016","journal-title":"Blood"},{"key":"key20180108133937_b11-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-\u03b1 therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"key20180108133937_b12-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180108133937_b13-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180108133937_b14-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1309\/AJCPUAAC16LIWZMM","article-title":"CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable","volume":"143","author":"Kim","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"key20180108133937_b15-etm-0-0-4077","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/etm.2017.4077\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T23:44:54Z","timestamp":1515455094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/etm.2017.4077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,23]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,1,23]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3892\/etm.2017.4077"],"URL":"https:\/\/doi.org\/10.3892\/etm.2017.4077","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,23]]}}}